- Poster presentations scheduled for the 16th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting on Wednesday October 25th – Friday October 27th, 2023, in Boston, Massachusetts.
BELFAST, Northern Ireland and CAMBRIDGE, Mass., October 18, 2023 / — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, will present data at the Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting on Wednesday October 25th – Friday October 27th in Boston, Massachusetts.
Three (3) poster presentations have been accepted by the CTAD Scientific Program Committee, two featuring internally generated data collected from Cumulus-sponsored studies partnering with academic and clinical institutions, and one featuring data generated from a biopharma customer sponsored study.
All three poster presentations will take place on October 25th, 26th and 27th from 7:30 – 8:30 AM EST and during coffee breaks at the Boston Park Plaza:
- Title: A real-world, longitudinal observational study in patients with Alzheimer’s Disease dementia and healthy controls, using frequent repeated digital measurements performed at-home on the Cumulus Platform: a preliminary report
- Poster Number: 183
- Title: Feasibility of the Cumulus electrophysiological neurocognitive platform to enable de-centralized trials in Alzheimer’s Disease
- Poster Number: 186
- Title: Validating a novel digital cognitive platform: sensitivity to change following an alcohol challenge
- Poster Number: 180
Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function. To learn more, visit www.cumulusneuro.com.
About Cumulus Neuroscience
With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world’s leading pharma companies, the platform enables decentralized trials, and is already making a difference in the development of therapies for Alzheimer’s Disease, depression and schizophrenia.
Designed to provide an industry-wide standard for real-world measurement of disease progression, Cumulus combines patented technology, in-house expertise and key industry partnerships to capture large amounts of real-world, clinical data repeated over time, across multiple behavioral and physiological domains in the patient’s home – all with an EEG headset synced to a novel, tablet-based neuro-assessment platform. Together with machine learning (ML) analytics and the world’s largest database of annotated, longitudinal, neurofunctional data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the best and most cost-effective assessment of CNS treatment outcomes.
The Company is supported by highly experienced specialized investors, DDF/SV Health Investors, LifeArc and Future Fund, and a world-class Scientific and Technical Advisory Board.
FOR MORE INFORMATION
Julie Dietel
FINN Partners for Cumulus
julie.dietel@finnpartners.com
Tel: 978.502.7705
SOURCE Cumulus Neuroscience